KROS
Keros Therapeutics, Inc.
$10.00
-2.91%
$199.3M
No data for this timeframe.
Vol
Market Cap$199.3M
Cap SizeMicro Cap
Inst. Holders8 funds
Inst. Value$61.5M
Inst. Activity3 buys / 5 sells
Insider Activity3B / 7S
Insider Net $-$371.6K
SEC Reports8
Press Releases2
Recent Activity
Jun 8, 2026
SEC
Two Keros Therapeutics directors sold a combined $56K in open-market sales on June 4, 2026, following a round of non-cas
CLUSTER — Impact 2/10
Jun 4, 2026
Insider
Seth Alpna sold 2,625 shares
Director @ $10.72 ($28.1K)
Jun 4, 2026
Insider
Farzan Nima sold 2,625 shares
Director @ $10.73 ($28.2K)
Jun 4, 2026
Insider
Knowles Julius sold 2,625 shares
Director @ $10.73 ($28.2K)
Jun 1, 2026
other
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
<p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq:
May 14, 2026
SEC
Keros Therapeutics reported Q1 2026 results with a net loss of $23.7M ($1.21/share) vs net income of $148.5M ($3.66/shar
8-K — Impact 5/10
May 14, 2026
SEC
Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue of $0.367M, 78.4% be
PRESS-RELEASE — Impact 6/10
Inst.
VANGUARD GROUP INC — TRIM
1,525,355 shares ($31.1M)
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$21.83 (Mar 2026)
Current $10.07
Low $16.00
Median $20.00
High $30.00
6 analysts
$16.00
$30.00
Analyst Ratings
3Strong Buy
6Buy
5Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 5, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.24 ▼ -6.9% | $-1.33 — $-1.20 | -63% YoY | 5 |
| Next Q | $-1.30 ▼ -3.8% | $-1.56 — $-1.11 | -621% YoY | 5 |
| Current FY | $-5.19 ▼ -11.0% | $-5.96 — $-4.83 | -325% YoY | 5 |
| Next FY | $-5.59 ▼ -10.7% | $-8.60 — $-2.45 | -8% YoY | 6 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two Keros Therapeutics directors sold a combined $56K in open-market sales on June 4, 2026, following a round of non-cas
Jun 8, 2026
BEARISH
8-K
5/10
Keros Therapeutics reported Q1 2026 results with a net loss of $23.7M ($1.21/share) vs net income of $148.5M ($3.66/shar
May 14, 2026
BULLISH
Press
7/10
Keros Therapeutics presented additional Phase 1 data for rinvatercept (KER-065) at a clinical conference, showing target
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $31.1M | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $12.0M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $6.5M | DOUBLED |
| MORGAN STANLEY | $4.7M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.8M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Seth Alpna | SELL | $28.1K |
| Jun 4, 2026 | Farzan Nima | SELL | $28.2K |
| Jun 4, 2026 | Knowles Julius | SELL | $28.2K |
| Jun 3, 2026 | Knowles Julius | A | $0.00 |
| Jun 3, 2026 | Farzan Nima | A | $0.00 |
8 institutional holders with $61.5M total value (3,021,224 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net selling activity: 5 institutions trimmed/exited vs 3 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,525,355 | $31.1M | 50.5% | TRIM -43.9% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 591,686 | $12.0M | 19.6% | DOUBLED +282.5% |
| 3 | TWO SIGMA INVESTMENTS, LP | 318,439 | $6.5M | 10.5% | DOUBLED +285.9% |
| 4 | MORGAN STANLEY | 230,492 | $4.7M | 7.6% | TRIM -41.7% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 186,779 | $3.8M | 6.2% | TRIM -36.0% |
| 6 | BANK OF AMERICA CORP /DE/ | 100,114 | $2.0M | 3.3% | TRIM -55.7% |
| 7 | FMR LLC | 35,597 | $724.8K | 1.2% | TRIM -64.6% |
| 8 | WELLS FARGO & COMPANY/MN | 32,762 | $667.0K | 1.1% | ADD +26.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | TRIM | 2,718,777 | 1,525,355 | -43.9% | $31.1M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 154,700 | 591,686 | +282.5% | $12.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 82,523 | 318,439 | +285.9% | $6.5M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 395,103 | 230,492 | -41.7% | $4.7M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 292,006 | 186,779 | -36.0% | $3.8M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 226,127 | 100,114 | -55.7% | $2.0M | 2025-Q4 |
| FMR LLC | TRIM | 100,531 | 35,597 | -64.6% | $724.8K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 25,890 | 32,762 | +26.5% | $667.0K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 878,746 | 395,103 | -55.0% | $6.3M | 2025-Q3 |
| FMR LLC | TRIM | 164,271 | 100,531 | -38.8% | $1.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 13,522 | 82,523 | +510.3% | $1.3M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 1,697,557 | 878,746 | -48.2% | $11.7M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 155,612 | 295,477 | +89.9% | $3.9M | 2025-Q2 |
| FMR LLC | TRIM | 441,540 | 164,271 | -62.8% | $2.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 146,600 | — | $2.0M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 16,778 | 21,945 | +30.8% | $293.0K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 62,372 | 13,522 | -78.3% | $180.5K | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 1,957,109 | 2,566,321 | +31.1% | $26.2M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 656,801 | 1,697,557 | +158.5% | $17.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 868,609 | 495,409 | -43.0% | $5.0M | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 5,543,308 | 441,540 | -92.0% | $4.5M | 2025-Q1 |
| UBS Group AG | TRIM | 174,941 | 92,429 | -47.2% | $941.9K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 33,664 | 62,372 | +85.3% | $635.6K | 2025-Q1 |
| NORGES BANK | EXIT | 64,900 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 365,297 | 656,801 | +79.8% | $10.4M | 2024-Q4 |
10 unique insiders with 10 transactions. Net insider value: -$371.6K ($44.7K bought, $416.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Seth Alpna | Director | SELL | 2,625 | $10.72 | $28.1K |
| Jun 4, 2026 | Farzan Nima | Director | SELL | 2,625 | $10.73 | $28.2K |
| Jun 4, 2026 | Knowles Julius | Director | SELL | 2,625 | $10.73 | $28.2K |
| Jun 3, 2026 | Knowles Julius | Director | A | 7,433 | $0.00 | $0.00 |
| Jun 3, 2026 | Farzan Nima | Director | A | 7,433 | $0.00 | $0.00 |
| Jun 3, 2026 | GRAY MARY ANN | Director | A | 7,433 | $0.00 | $0.00 |
| Jun 3, 2026 | Knowles Julius | Director | A | 7,142 | $0.00 | $0.00 |
| Jun 3, 2026 | BIENAIME JEAN JACQUES | Director | A | 7,142 | $0.00 | $0.00 |
| Jun 3, 2026 | BIENAIME JEAN JACQUES | Director | A | 7,433 | $0.00 | $0.00 |
| Jun 3, 2026 | GRAY MARY ANN | Director | A | 7,142 | $0.00 | $0.00 |
| Jun 3, 2026 | Farzan Nima | Director | A | 7,142 | $0.00 | $0.00 |
| Jun 3, 2026 | Seth Alpna | Director | A | 7,142 | $0.00 | $0.00 |
| Jun 3, 2026 | Seth Alpna | Director | A | 7,433 | $0.00 | $0.00 |
| May 15, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 1,000 | $10.58 | $10.6K |
| Apr 15, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 1,000 | $11.70 | $11.7K |
| Apr 2, 2026 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | M | 55,000 | $0.3000 | $16.5K |
| Apr 2, 2026 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | M | 55,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Newton Charles W. | Director | A | 13,215 | $0.00 | $0.00 |
| Mar 9, 2026 | Newton Charles W. | Director | A | 14,788 | $0.00 | $0.00 |
| Mar 9, 2026 | BIENAIME JEAN JACQUES | Director | BUY | 2,000 | $11.21 | $22.4K |
| Feb 24, 2026 | Cho Esther | Chief Legal Officer | A | 80,000 | $0.00 | $0.00 |
| Feb 24, 2026 | Regnante Keith | CHIEF FINANCIAL OFFICER | A | 60,000 | $0.00 | $0.00 |
| Feb 24, 2026 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | A | 217,000 | $0.00 | $0.00 |
| Feb 24, 2026 | Lerner Lorena Raquel | Chief Scientific Officer | A | 75,000 | $0.00 | $0.00 |
| Feb 24, 2026 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | A | 100,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | SELL | 7,015 | $16.17 | $113.4K |
| Feb 18, 2026 | Lerner Lorena Raquel | Chief Science Officer | SELL | 3,873 | $16.35 | $63.3K |
| Feb 18, 2026 | Cho Esther | SVP, General Counsel | SELL | 4,745 | $16.35 | $77.6K |
| Feb 18, 2026 | Regnante Keith | CHIEF FINANCIAL OFFICER | SELL | 4,739 | $16.35 | $77.5K |
8 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 2 mixed, 4 neutral. Avg impact: 4.3/10.
NEUTRAL
CLUSTER
2/10
Two Keros Therapeutics directors sold a combined $56K in open-market sales on June 4, 2026, followin
Jun 8, 2026
BEARISH
8-K
5/10
Keros Therapeutics reported Q1 2026 results with a net loss of $23.7M ($1.21/share) vs net income of
May 14, 2026
BEARISH
PRESS-RELEASE
6/10
Keros Therapeutics reported Q1 2026 EPS of -$1.21, a 31.5% miss vs consensus of -$0.92, and revenue
May 14, 2026
NEUTRAL
DEFA14A
3/10
Keros Therapeutics is holding its 2026 annual shareholder meeting virtually on June 3, 2026. The boa
Apr 22, 2026
NEUTRAL
144
3/10
OrbiMed Advisors LLC, on behalf of its affiliate OrbiMed Genesis Master Fund, LP, has filed a Form 1
Apr 1, 2026
MIXED
8-K
5/10
Keros Therapeutics updated its corporate presentation for investor meetings, disclosing clinical tri
Mar 4, 2026
NEUTRAL
8-K
5/10
{
"summary": "Keros Therapeutics reported a full-year net income of $87.0 million for 2025, a sign
Mar 4, 2026
MIXED
INST-CLUSTER
5/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — increased their positions
Feb 28, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 64% buy across 14 analysts — 3 strong buy, 6 buy, 5 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$21.83 mean target (Mar 2026)
$16.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $10.07 |
| Target Low | $16.00 |
| Target Mean | $21.83 |
| Target Median | $20.00 |
| Target High | $30.00 |
| # Analysts | 6 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.24 | $-1.33 | $-1.20 | -63.4% | -6.9% | 0↑ 4↓ | $0.0B | -96.1% | 5 |
| Next Q 2026-09-30 |
$-1.30 | $-1.56 | $-1.11 | -621.1% | -3.8% | 0↑ 4↓ | $0.0B | -90.2% | 5 |
| Current FY 2026-12-31 |
$-5.19 | $-5.96 | $-4.83 | -325.5% | -11.0% | 0↑ 4↓ | $0.0B | -98.3% | 5 |
| Next FY 2027-12-31 |
$-5.59 | $-8.60 | $-2.45 | -7.8% | -10.7% | 1↑ 3↓ | $0.0B | 344.7% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.242 | |
| 7d ago | $-1.250 | +0.008 |
| 30d ago | $-1.162 | -0.080 |
| 60d ago | $-1.162 | -0.080 |
| 90d ago | $-1.280 | +0.038 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 5, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 5 | 0 | 0 | 64% | |
| May 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Apr 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Mar 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Feb 1, 2026 | 5 | 6 | 5 | 0 | 0 | 69% | |
| Jan 1, 2026 | 5 | 6 | 5 | 0 | 0 | 69% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
other
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
<p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company
May 14, 2026
earnings
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
<p>LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharma
May 4, 2026
earnings_calendar
KROS Q1 2026 Earnings Before Market Open — 2026-05-04
Apr 30, 2026
earnings_calendar
KROS Q1 2026 Earnings Before Market Open — 2026-04-30
Mar 9, 2026
fda
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
<p>LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biophar
Mar 4, 2026
earnings
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
<p>LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biophar
Mar 4, 2026
earnings_calendar
KROS Q4 2025 Earnings After Market Close — 2026-03-04
Mar 2, 2026
earnings_calendar
KROS Q4 2025 Earnings After Market Close — 2026-03-02
Feb 25, 2026
short_interest
FTD: KROS — 59,364 shares ($0.9M) failed to deliver
Settlement: 20260225, Price: $15.52, FTD Value: $921,329.28, KEROS THERAPEUTICS INC COM